• 
  Ingrid Masson, Laurène Larriviere, Marc-André Mahé, David Azria, Pascal Pommier, et al.. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer. Clinical and Translational Radiation Oncology, 2024, 44, pp.100702. ⟨10.1016/j.ctro.2023.100702⟩. ⟨hal-04813716⟩
• 
  Sarah Atallah, Odile Casiraghi, Nicolas Fakhry, Michel Wassef, Emmanuelle Uro-Coste, et al.. A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. European journal of cancer, 2020, 130, pp.241-249. ⟨10.1016/j.ejca.2020.01.023⟩. ⟨hal-03599053⟩
• 
  Simon Baldacci, Benjamin Besse, Virginie Avrillon, Bertrand Mennecier, Julien Mazieres, et al.. Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. European Journal of Cancer, 2022, 166, pp.51-59. ⟨10.1016/j.ejca.2022.01.018⟩. ⟨hal-04728569⟩
• 
  Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, et al.. Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. The Breast, 2021, 57, pp.43-48. ⟨10.1016/j.breast.2021.02.014⟩. ⟨hal-04769597⟩
• 
  Joël Guigay, Hervé Le Caer, François-Régis Ferrand, Lionel Geoffrois, Esma Saada-Bouzid, et al.. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial. The Lancet. Healthy longevity, 2024, 5 (6), pp.e392-e405. ⟨10.1016/S2666-7568(24)00048-5⟩. ⟨hal-04578230⟩
• 
  Francois Gouin, Audrey Michot, Mehrdad Jafari, Charles Honoré, Jean Camille Mattei, et al.. Improved metastatic-free survival after systematic re-excision following complete macroscopic unplanned excision of limb or trunk soft tissue sarcoma. Cancers, 2024, 16 (7), pp.1365. ⟨10.3390/cancers16071365⟩. ⟨hal-04653665⟩
• 
  Rayan Kabirian, Maria Alice Franzoi, Julie Havas, Charles Coutant, Olivier Trédan, et al.. Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer. JAMA Network Open, 2023, 6 (11), pp.e2343910. ⟨10.1001/jamanetworkopen.2023.43910⟩. ⟨hal-04765786⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. New England Journal of Medicine, 2024, 391 (9), pp.789-799. ⟨10.1056/NEJMoa2403394⟩. ⟨inserm-04761524⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  B. Cuer, C. Mollevi, A. Anota, E. Charton, B. Juzyna, et al.. Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17. BMC Medical Research Methodology, 2020, 20 (1), pp.223. ⟨10.1186/s12874-020-01104-w⟩. ⟨hal-03696198⟩
• 
  Julien Guérin, Amine Nahid, Louis Tassy, Marc Deloger, François Bocquet, et al.. Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research. International Journal of Environmental Research and Public Health, 2024, 21 (2), pp.189. ⟨10.3390/ijerph21020189⟩. ⟨inserm-04659888⟩
• 
  J.Y. Blay, N. Penel, T. Valentin, P. Anract, F. Duffaud, et al.. Improved nationwide survival of sarcoma patients with a network of reference centers. Annals of Oncology, 2024, 35 (4), pp.351-363. ⟨10.1016/j.annonc.2024.01.001⟩. ⟨inserm-04658953⟩
• 
  A. Le Cesne, J. Y. Blay, D. Cupissol, A. Italiano, C. Delcambre, et al.. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Annals of Oncology, 2021, Annals of Oncology, 32 (8), p. 1034-1044. ⟨10.1016/j.annonc.2021.04.014⟩. ⟨hal-04522981⟩
• 
  É. Mathian, Y. Drouet, A. Sexton-Oates, M.G. Papotti, G. Pelosi, et al.. Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project. ESMO Open, 2024, 9 (6), pp.103591. ⟨10.1016/j.esmoop.2024.103591⟩. ⟨hal-04655442⟩
• 
  Antonio Di Meglio, Elise Martin, Tracy E Crane, Cecile Charles, Aude Barbier, et al.. A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. Trials, 2022, 23 (1), pp.193. ⟨10.1186/s13063-022-06090-6⟩. ⟨inserm-04614681⟩
• 
  Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
• 
  Marc Hilmi, Alice Boilève, Anabelle Ducousso, Morgan Michalet, Anthony Turpin, et al.. Professional and Psychological Impacts of the COVID-19 Pandemic on Oncology Residents: A National Survey. JCO Global Oncology, 2020, 6, pp.1674-1683. ⟨10.1200/go.20.00376⟩. ⟨hal-04548023⟩
• 
  P. Kubicek, A. L. Cesne, C. Lervat, M. Toulmonde, C. Chevreau, et al.. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.. BMC Cancer, 2023, BMC Cancer, 23 (1), pp.69. ⟨10.1186/s12885-023-10556-4⟩. ⟨hal-04315885⟩
• 
  Pauline Marolleau, David Tougeron, Benoit Allignet, Romain Cohen, David Sefrioui, et al.. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. International Journal of Cancer, 2023, ⟨10.1002/ijc.34636⟩. ⟨hal-04154476⟩

138

222